αvβ3 integrin and angiogenesis: a moody integrin in a changing environment

Current Opinion in Cell Biology

Volumn 20, Issue 5, 2008, Pages 514-519

  Hodivala Dilke, Kairbaan ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; CILENGITIDE; MONOCLONAL ANTIBODY LM 609; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CLINICAL TRIAL; DRUG EFFECT; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; CELL DEATH; DRUG ANTAGONISM; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DEATH; HUMANS; INTEGRIN ALPHAVBETA3; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 51049108993     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceb.2008.06.007     Document Type: Review

References (45)

1. Adams R.H., and Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8 (2007) 464-478
2. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002) 673-687
3. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1992) 11-25
4. Hodivala-Dilke K.M., Reynolds A.R., and Reynolds L.E. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 314 (2003) 131-144
5. Brooks P.C., Clark R.A., and Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994) 569-571
6. Drake C.J., Cheresh D.A., and Little C.D. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 108 Pt 7 (1995) 2655-2661
7. Eliceiri B.P., and Cheresh D.A. The role of alphav integrins during angiogenesis. Mol Med 4 (1998) 741-750
8. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., and Cheresh D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96 (1995) 1815-1822
9. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., and Cheresh D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270 (1995) 1500-1502
10. Friedlander M., Theesfeld C.L., Sugita M., Fruttiger M., Thomas M.A., Chang S., and Cheresh D.A. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A 93 (1996) 9764-9769
11. Gutheil J.C., Campbell T.N., Pierce P.R., Watkins J.D., Huse W.D., Bodkin D.J., and Cheresh D.A. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6 (2000) 3056-3061
12. Nabors L.B., Mikkelsen T., Rosenfeld S.S., Hochberg F., Akella N.S., Fisher J.D., Cloud G.A., Zhang Y., Carson K., Wittemer S.M., et al. Phase I and correlative biology study of Cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25 (2007) 1651-1657. This study provides an example of the efficacy of the αvβ3 integrin antagonist, Cilengitide, in the treatment of malignant glioma in humans.
13. Stupp R., and Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 25 (2007) 1637-1638
14. Hariharan S., Gustafson D., Holden S., McConkey D., Davis D., Morrow M., Basche M., Gore L., Zang C., O'Bryant C.L., et al. Assessment of the biological and pharmacological effects of the alphav beta3 and alphav beta5 integrin receptor antagonist, Cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18 (2007) 1400-1407
15. Eskens F.A., Dumez H., Hoekstra R., Perschl A., Brindley C., Bottcher S., Wynendaele W., Drevs J., Verweij J., and van Oosterom A.T. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39 (2003) 917-926
16. Friess H., Langrehr J.M., Oettle H., Raedle J., Niedergethmann M., Dittrich C., Hossfeld D.K., Stoger H., Neyns B., Herzog P., et al. A randomized multi-center Phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6 (2006) 285-297
17. Bader B.L., Rayburn H., Crowley D., and Hynes R.O. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95 (1998) 507-519
18. Lacy-Hulbert A., Smith A.M., Tissire H., Barry M., Crowley D., Bronson R.T., Roes J.T., Savill J.S., and Hynes R.O. Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc Natl Acad Sci U S A 104 (2007) 15823-15828. Using a Tie2-driven Cre-recombinase system these authors deleted αv integrins in the hemangioblasts and endothelium of mice and showed that this did not appear to affect angiogenesis. This work describes that the loss of αv integrins in the endothelium of adult mice is not sufficient to affect blood vessel morphology.
19. Hodivala-Dilke K.M., McHugh K.P., Tsakiris D.A., Rayburn H., Crowley D., Ullman-Cullere M., Ross F.P., Coller B.S., Teitelbaum S., and Hynes R.O. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 103 (1999) 229-238
20. Huang X., Griffiths M., Wu J., Farese Jr. R.V., and Sheppard D. Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice. Mol Cell Biol 20 (2000) 755-759
21. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., Sheppard D., Hynes R.O., and Hodivala-Dilke K.M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8 (2002) 27-34
22. Taverna D., Crowley D., Connolly M., Bronson R.T., and Hynes R.O. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 65 (2005) 10324-10329
23. Law D.A., DeGuzman F.R., Heiser P., Ministri-Madrid K., Killeen N., and Phillips D.R. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 401 (1999) 808-811
24. Mahabeleshwar G.H., Feng W., Phillips D.R., and Byzova T.V. Integrin signaling is critical for pathological angiogenesis. J Exp Med 203 (2006) 2495-2507. Here the authors elegantly utilize mutant β3 integrin knockin mice, DiYF, where the tyrosine 747 and 459 motifs of the β3 subunit have been substituted with phenylanalines rendering an outside-in non-functioning mutation. These mice display severely inhibited tumor growth and angiogenesis indicating that these tyrosine motifs are positively involved in tumor angiogenesis.
25. Reynolds A.R., Reynolds L.E., Nagel T.E., Lively J.C., Robinson S.D., Hicklin D.J., Bodary S.C., and Hodivala-Dilke K.M. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res 64 (2004) 8643-8650
26. Robinson S.D., Reynolds L.E., Wyder L., Hicklin D.J., and Hodivala-Dilke K.M. Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol 24 (2004) 2108-2114
27. Soldi R., Mitola S., Strasly M., Defilippi P., Tarone G., and Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 18 (1999) 882-892
28. Diaz-Gonzalez F., Forsyth J., Steiner B., and Ginsberg M.H. Trans-dominant inhibition of integrin function. Mol Biol Cell 7 (1996) 1939-1951
29. Hodivala-Dilke K.M., DiPersio C.M., Kreidberg J.A., and Hynes R.O. Novel roles for alpha3beta1 integrin as a regulator of cytoskeletal assembly and as a trans-dominant inhibitor of integrin receptor function in mouse keratinocytes. J Cell Biol 142 (1998) 1357-1369
30. Hamano Y., Zeisberg M., Sugimoto H., Lively J.C., Maeshima Y., Yang C., Hynes R.O., Werb Z., Sudhakar A., and Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3 (2003) 589-601
31. Maeshima Y., Colorado P.C., and Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275 (2000) 23745-23750
32. Maeshima Y., Sudhakar A., Lively J.C., Ueki K., Kharbanda S., Kahn C.R., Sonenberg N., Hynes R.O., and Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295 (2002) 140-143
33. Kalluri R. Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harb Symp Quant Biol 67 (2002) 255-266
34. Kawaguchi T., Yamashita Y., Kanamori M., Endersby R., Bankiewicz K.S., Baker S.J., Bergers G., and Pieper R.O. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res 66 (2006) 11331-11340
35. Stupack D.G., Puente X.S., Boutsaboualoy S., Storgard C.M., and Cheresh D.A. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 155 (2001) 459-470
36. Maubant S., Saint-Dizier D., Boutillon M., Perron-Sierra F., Casara P.J., Hickman J.A., Tucker G.C., and Van Obberghen-Schilling E. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 108 (2006) 3035-3044
37. Jones M.C., Caswell P.T., and Norman J.C. Endocytic recycling pathways: emerging regulators of cell migration. Curr Opin Cell Biol 18 (2006) 549-557. This is an insightful review that describes the biology of integrin recycling and its possible functions in migrating cells.
38. Mahabeleshwar G.H., Feng W., Reddy K., Plow E.F., and Byzova T.V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 101 (2007) 570-580
39. De S., Razorenova O., McCabe N.P., O'Toole T., Qin J., and Byzova T.V. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A 102 (2005) 7589-7594
40. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., Ferrara N., Nagy A., Roos K.P., and Iruela-Arispe M.L. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130 (2007) 691-703
41. Legler D.F., Wiedle G., Ross F.P., and Imhof B.A. Superactivation of integrin alphavbeta3 by low antagonist concentrations. J Cell Sci 114 (2001) 1545-1553
42. Mahabeleshwar G.H., Chen J., Feng W., Somanath P.R., Razorenova O.V., and Byzova T.V. Integrin affinity modulation in angiogenesis. Cell Cycle 7 (2008) 335-347
43. Gerhardt H., Golding M., Fruttiger M., Ruhrberg C., Lundkvist A., Abramsson A., Jeltsch M., Mitchell C., Alitalo K., Shima D., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161 (2003) 1163-1177
44. Yan W., Bentley B., and Shao R. Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol Biol Cell 19 (2008) 2278-2288
45. Naik M.U., and Naik U.P. Junctional adhesion molecule-A-induced endothelial cell migration on vitronectin is integrin alpha v beta 3 specific. J Cell Sci 119 (2006) 490-499